Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo
Important Safety Information | Patient Site
Prescribing Information
    • How it Works
    • Patient Use Cases
    • Prophylaxis
    • On Demand
    • Perioperative
    • Safety Profile
    • Pharmacokinetics
    • FIX PK Comparisons
    • Comparative Modeling
    • Simplified Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo

For use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. See Limitations of Use below.

Prescribing Information
Important Safety Information | Patient Site

Once-weekly prophylaxis that fits into life’s routines1

Unlike with other Factor IX (FIX) products, with Rebinyn® there’s no need to calculate desired FIX activity levels to determine the appropriate dose.1-6

Clayton has hemophilia B
and uses Rebinyn®.

Once-weekly prophylaxis that fits into life’s routines1

Unlike with other Factor IX (FIX) products, with Rebinyn® there’s no need to calculate desired FIX activity levels to determine the appropriate dose.1-6

Clayton has hemophilia B
and uses Rebinyn®.

Are you interested in the Novo Nordisk Lab Program? Click here or scroll below.

Recommended dose for routine prophylaxis1

Simple once-weekly dosing helps patients maintain high FIX levels and be ready for the unexpected.1

1x

weekly dosing

40

IU/kg

Dosing regimen can be adjusted based on individual patient’s bleeding pattern and physical activity.

Almost two-thirds of patients taking extended half-life therapies use once-weekly dosing regiments.7,a

aBased on American Thrombosis and Hemostasis Network (ATHN) Dataset, the proportion of subjects with severe hemophilia on prophylaxis were compared to those on demand by age cohort in June 2018 and March 2019. The proportion of subjects on prophylaxis was analyzed by race, ethnicity, insurance status, and hemophilia treatment center region. Treatment frequency for subjects receiving prophylaxis with extended half-life (EHL) was analyzed.7


Flexible bleed control with on-demand dosing

40

IU/kg

for minor or moderate bleeds1

80

IU/kg

for major bleeds1

A single dose of 40 IU/kg should be sufficient for minor and moderate bleeds. For major bleeds, treat with 80 IU/kg. For all bleed types, additional doses of 40 IU/kg can be given.1


Dosing for perioperative management1

Type of Surgical Procedure

Recommended dose

Additional information

Type of Surgical Procedure

Minor
For example: Implanting pumps in subcutaneous tissue, skin biopsies, or simple dental procedures.

Recommended dose

40 IU/kg1

Additional information

A single pre-operative dose should be sufficient. Additional doses can be given if needed.

Type of Surgical Procedure

Major
For example: Body cavity is entered, mesenchymal barrier is crossed, fascial plane is opened, organ is removed, and normal anatomy is operatively altered.

Recommended dose

80 IU/kg1

Additional information

Pre-operative dose.


Recommended dose

40 IU/kg1

Additional information

As clinically needed for the perioperative management of bleeding, repeated doses of 40 IU/kg (in 1- to 3-day intervals) within the first week after major surgery may be administered. 
Due to the long half-life of Rebinyn®, the frequency of dosing in the post-surgical setting may be extended to once weekly after the first week until bleeding stops and healing is achieved.

Select features of FIX products1-6

Factor IX product feature comparison
Factor IX product feature comparison

The above table is not intended to be a comparison of efficacy or safety.

Test tube and blood droplet icon

LabCorp™ partnership helps you monitor FIX levels

Factor IX activity assay results may be significantly affected by the type of aPTT reagent, which can result in over- or under-estimation of FIX activity. Rebinyn® FIX activity levels and inhibitor testing are available through the Novo Nordisk Lab Program, using validated assays in compliance with CAP/CLIA regulations.

To activate your Labcorp™ account and participate in the program, download and complete the form, then email it to fixsupport@labcorp.com.


Flexible storage for patients on-the-go

Rebinyn® does not require refrigeration. It can be stored at room temperature (up to 86˚F) for up to 6 months and for up to 4 hours after reconstitution.

Requires no refrigeration up to 86˚F.1

Room temperature stable


for up to 6 months

Post-reconstitution storage


for up to 4 hours

If you choose to store Rebinyn® at room temperature, do not return it to the refrigerator. Rebinyn® vials can also be stored in the refrigerator at 36˚F–46˚F for up to 24 months or until the expiration date stated on the label. Please see Prescribing Information for complete storage instructions.


What does Rebinyn® offer patients like Landen?

Landen is 31, lives with moderate hemophilia B, and leads a busy lifestyle—including frequent travel for work. Explore the features of Rebinyn® that may make it an appropriate factor IX therapy for him.

See patient profiles
 Silhouette of man

For illustrative purposes.

Established safety profile

Medicine vial and checklist icon

Clinical trials showed 0 inhibitors and thrombotic events in previously treated patients in 5 clinical trials over 13 years.1,8

View the data

The formation of inhibitors (neutralizing antibodies) to Factor IX (FIX) has occurred following Rebinyn®. Common adverse reactions (≥1%) in previously untreated patients reported in clinical trials included FIX inhibitors.

Powerful bleed protection

Blood Protection icon

Studies show Rebinyn® prophylaxis helps prevent spontaneous and traumatic bleeds.1

See the data

Selected Important Safety Information for Rebinyn®

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

  • Hypersensitivity Reactions: Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with Rebinyn®. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic- or anaphylactic-type reactions occur and initiate appropriate treatment.

Indications and Usage

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B (congenital Factor IX deficiency) for on demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. 

Limitations of Use: Rebinyn® is not indicated for immune tolerance induction in patients with hemophilia B.

Important Safety Information

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

  • Hypersensitivity Reactions: Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with Rebinyn®. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic- or anaphylactic-type reactions occur and initiate appropriate treatment.
  • Inhibitors: The formation of inhibitors (neutralizing antibodies) to Factor IX has occurred following Rebinyn®. If expected plasma factor IX activity levels are not attained, or if bleeding is not controlled as expected with the administered dose, perform an assay that measures Factor IX inhibitor concentration. Monitor all patients using clinical observations and laboratory tests for the development of inhibitors. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used.
  • Thrombotic Events: The use of Factor IX-containing products has been associated with thromboembolic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC).
  • Nephrotic Syndrome: Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established.

Adverse Reactions

  • The most common adverse reactions reported in previously treated patients in clinical trials (≥1%) were itching and injection site reactions. The most common adverse reactions (≥1%) in previously untreated patients reported in clinical trials were rash, FIX inhibitors, hypersensitivity, itching, injection site reaction, and anaphylactic reaction.
  • Animals administered Rebinyn® showed accumulation of PEG in the choroid plexus, pituitary, circumventricular organs, and cranial motor neurons. The potential clinical implications of these animal findings are unknown. Consider whether the patient is vulnerable to cognitive impairment, such as infants and children who have developing brains, and patients who are cognitively impaired.

Please click here for Rebinyn® Prescribing Information.

References:

  1. Rebinyn [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2022. 
  2. Benefix [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2021. 
  3. Alprolix [package insert]. Cambridge, MA: Biogen Inc; 2018. 
  4. Idelvion [package insert]. Kankakee, IL: CSL Behring LLC; 2020. 
  5. Ixinity [package insert]. Berwyn, PA: Aptevo BioTherapeutics LLC; 2021.
  6. Rixubis [package insert]. Westlake Village, CA: Baxalta Healthcare Corporation; 2020.
  7. Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960-965.
  8. Novo Nordisk A/S. Safety of 40K PEGylated recombinant Factor IX in non-bleeding patients with haemophilia B. ClinicalTrials.gov identifier: NCT00956345. Updated January 20, 2017. Accessed June 3, 2022. https://clinicaltrials.gov/ct2/show/NCT00956345
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoCare® and Rebinyn® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US22REB00204 March 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials